Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance
Journal of Clinical Lipidology, 07/26/2011Kennedy SP et al.
Once–weekly low–dose rosuvastatin is an effective and well–tolerated lipid–lowering therapy option for patients not at low–density lipoprotein (LDL) goal and previously unable to tolerate statins because of a history of myalgias.
In this randomized, double–blind, placebo–controlled crossover study
Authors enrolled total of 17 Clement J. Zablocki Veterans Affairs (VA) primary care patients with a diagnosis of hyperlipidemia and a history of myalgias on statin therapy who were not currently on a statin and not at LDL goal
Two 8–week treatment phases consisted of rosuvastatin 5 mg once–weekly or matching placebo, with a dose titration to 10 mg once–weekly if not at LDL goal at week 4
The primary efficacy outcome was the difference in the mean percentage change in LDL from baseline between rosuvastatin and placebo
A significant difference in the mean percentage change in LDL from baseline for rosuvastatin vs. placebo was identified (12.2% reduction vs. 0.4% reduction, respectively; P = .002)
2 of 17 patients (11.8%) in placebo treatment phase and 3 of 15 patients (20%) in rosuvastatin treatment phase experienced myalgias requiring cessation of therapy
3 patients (20%) were able to attain LDL goal on rosuvastatin compared with zero patients (0%) on placebo
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.